Tom G. Punnen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tom G. Punnen has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Darin T. Okuda
The University of Texas Southwestern Medical Center, Department of Neurology, Neuroinnovation Program, Multiple Sclerosis & Neuroimmunology Imaging Program, Dallas, TX, USA; The University of Texas Southwestern Medical Center, Peter O'Donnell Jr. Brain Institute, Dallas, TX, USA
2 shared publications - Mahi A. Patel
College of Osteopathic Medicine, Kansas City University, Kansas City, MO, USA
2 shared publications - Morgan McCreary
Department of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Peter O’Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, USA
2 shared publications - Olaf Stüve
Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
2 shared publications - Peter V. Sguigna
Department of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Peter O’Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, USA
2 shared publications - Tatum M. Moog
From the The University of Texas Southwestern Medical Center (D.T.O., T.G.P., T.M.M., M.C.M., K.W.B.), Department of Neurology, Neuroinnovation Program, Multiple Sclerosis & Neuroimmunology Imaging Program, Dallas, Texas
2 shared publications
Latest Publications
- Open Access
- 6 March 2026
- Published by Elsevier in SSRN Electronic Journal
Selective Multi-Analyte Serum Protein Differences Between Gilenya and Generic Fingolimod in Multiple Sclerosis
- 6 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSelective Multi-Analyte Serum Protein Differences Between Gilenya and Generic Fingolimod in Multiple Sclerosis
- Open Access
- 3 January 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (2) , 192-201
Clinical and radiological outcomes of directed treatment transitions from Gilenya ® to generic fingolimod
Background: Gilenya ® (fingolimod), a sphingosine-1-receptor agonist, is an effective treatment for multiple sclerosis (MS). However, increased relapse activity has been observed after transitioning to generic fingolimod despite prior prolonged disease stability. Objective: To quantify the clinical and radiological impact of transitioning from Gilenya ® to generic fingolimod in people with MS (PwMS). Methods: Retrospective data were evaluated from a single tertiary MS care center. Time to magnetic resonance imaging (MRI) activity and clinical relapse was assessed during Gilenya ® and generic fingolimod treatment. Differences in absolute lymphocyte count (ALC) and side effects were also measured by treatment group. Results: The cohort included 88 PwMS (71 female; 76 White, mean age when starting Gilenya ® was 39.6 years (standard deviation (SD) = 10.6 years), and mean age when starting generic fingolimod was 46.9 years (SD = 11.2 years)). A shorter time to MRI activity ( p = 0.0026) and time to relapse ( p = 0.0027) was observed during generic fingolimod treatment. The ALC increased by 8.81% after generic fingolimod treatment, relative to Gilenya ® (95% CI = (2.00%, 16.08%), p = 0.01), with an intersubject variability of 1.97%. A 2.45-fold increase in side effects was observed with generic fingolimod relative to Gilenya ® (95% CI = (1.38, 4.36), p = 0.002). Conclusion: Measures of disease stability appear less optimal with generic fingolimod based on serological, clinical, and radiological measures.
- 3 January 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (2) , 192-201
Open AccessClinical and radiological outcomes of directed treatment transitions from Gilenya ® to generic fingolimod
Background: Gilenya ® (fingolimod), a sphingosine-1-receptor agonist, is an effective treatment for multiple sclerosis (MS). However, increased relapse activity has been observed after transitioning to generic fingolimod despite prior prolonged disease stability. Objective: To quantify the clinical and radiological impact of transitioning from Gilenya ® to generic fingolimod in people with MS (PwMS). Methods: Retrospective data were evaluated from a single tertiary MS care center. Time to magnetic resonance imaging (MRI) activity and clinical relapse was assessed during Gilenya ® and generic fingolimod treatment. Differences in absolute lymphocyte count (ALC) and side effects were also measured by treatment group. Results: The cohort included 88 PwMS (71 female; 76 White, mean age when starting Gilenya ® was 39.6 years (standard deviation (SD) = 10.6 years), and mean age when starting generic fingolimod was 46.9 years (SD = 11.2 years)). A shorter time to MRI activity ( p = 0.0026) and time to relapse ( p = 0.0027) was observed during generic fingolimod treatment. The ALC increased by 8.81% after generic fingolimod treatment, relative to Gilenya ® (95% CI = (2.00%, 16.08%), p = 0.01), with an intersubject variability of 1.97%. A 2.45-fold increase in side effects was observed with generic fingolimod relative to Gilenya ® (95% CI = (1.38, 4.36), p = 0.002). Conclusion: Measures of disease stability appear less optimal with generic fingolimod based on serological, clinical, and radiological measures.
- Open Access
- 24 September 2025
- Published by JMIR Publications Inc. in Journal of Participatory Medicine
- Vol. 17, e69942
Patient Participation in AI for Health Curriculum
The adoption of artificial intelligence (AI) in health care has outpaced education of the clinical workforce on responsible use of AI in patient care. Although many policy statements advocate safe, ethical, and trustworthy AI, guidance on the use of health AI has rarely included patient perspectives. This gap leaves out a valuable source of information and guidance about what responsible AI means to patients. In this viewpoint coauthored by patients, students, and faculty, we discuss a novel approach to integrating patient perspectives in undergraduate premedical education in the United States that aims to foster an inclusive and patient-centered future of AI in health care.
- 24 September 2025
- Published by JMIR Publications Inc. in Journal of Participatory Medicine
- Vol. 17, e69942
Open AccessPatient Participation in AI for Health Curriculum
The adoption of artificial intelligence (AI) in health care has outpaced education of the clinical workforce on responsible use of AI in patient care. Although many policy statements advocate safe, ethical, and trustworthy AI, guidance on the use of health AI has rarely included patient perspectives. This gap leaves out a valuable source of information and guidance about what responsible AI means to patients. In this viewpoint coauthored by patients, students, and faculty, we discuss a novel approach to integrating patient perspectives in undergraduate premedical education in the United States that aims to foster an inclusive and patient-centered future of AI in health care.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 17
Clinical and radiological implications of subpotent generic fingolimod in multiple sclerosis: a case series
An expansion in the availability of generic specialty disease modifying therapies (DMTs) for treatment of multiple sclerosis (MS) has increased recently. Generic specialty medications aim to provide greater access to molecules that alter the disease trajectory at lower costs. The US Food and Drug Administration requires generic products to contain between 90% and 110% of the stated active ingredient and an 80%–125% bioequivalence range. We present the clinical experiences and absolute lymphocyte counts (ALC) trends of six people with MS originally treated with Gilenya® (fingolimod) 0.5 mg who were required to transition to generic fingolimod 0.5 mg by third-party administrators, and the medication content from recovered products. Six individuals with acute clinical exacerbations or disease advancement on MRI were identified during routine scheduled visits from a tertiary care center and consecutively included from January 2024 to August 2024. ALC trends were constructed for each individual during Gilenya® and generic fingolimod treatment. These individuals experienced signs of disease advancement while on generic fingolimod 0.5 mg at approximately 1 year of treatment and elevations in ALC, a biological metric related to the mechanism of action of sphingsine-1-phosphate receptor modulation, were observed following the transition. High purity fingolimod for standardization tests, Gilenya® 0.5 mg, and five recovered generic fingolimod 0.5 mg products were independently tested in an accredited laboratory. Gilenya® 0.5 mg capsules had an average fingolimod content of 97.7% (standard deviation (SD) = 2.59%). Three recovered generic fingolimod 0.5 mg products used during relapses had an average content of 91.2% (3.25%), 81.6% (6.24%), and 72.5% (2.05%). Two generic fingolimod 0.5 mg products not associated with relapse activity revealed averages of 97.4% (1.82%) and 103.3% (3.77%). Subpotent generic specialty DMTs may not only result in greater risk for disease activity but may also expose individuals to the potential for disease rebound, depending on the mechanism of action.
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 17
Open AccessClinical and radiological implications of subpotent generic fingolimod in multiple sclerosis: a case series
An expansion in the availability of generic specialty disease modifying therapies (DMTs) for treatment of multiple sclerosis (MS) has increased recently. Generic specialty medications aim to provide greater access to molecules that alter the disease trajectory at lower costs. The US Food and Drug Administration requires generic products to contain between 90% and 110% of the stated active ingredient and an 80%–125% bioequivalence range. We present the clinical experiences and absolute lymphocyte counts (ALC) trends of six people with MS originally treated with Gilenya® (fingolimod) 0.5 mg who were required to transition to generic fingolimod 0.5 mg by third-party administrators, and the medication content from recovered products. Six individuals with acute clinical exacerbations or disease advancement on MRI were identified during routine scheduled visits from a tertiary care center and consecutively included from January 2024 to August 2024. ALC trends were constructed for each individual during Gilenya® and generic fingolimod treatment. These individuals experienced signs of disease advancement while on generic fingolimod 0.5 mg at approximately 1 year of treatment and elevations in ALC, a biological metric related to the mechanism of action of sphingsine-1-phosphate receptor modulation, were observed following the transition. High purity fingolimod for standardization tests, Gilenya® 0.5 mg, and five recovered generic fingolimod 0.5 mg products were independently tested in an accredited laboratory. Gilenya® 0.5 mg capsules had an average fingolimod content of 97.7% (standard deviation (SD) = 2.59%). Three recovered generic fingolimod 0.5 mg products used during relapses had an average content of 91.2% (3.25%), 81.6% (6.24%), and 72.5% (2.05%). Two generic fingolimod 0.5 mg products not associated with relapse activity revealed averages of 97.4% (1.82%) and 103.3% (3.77%). Subpotent generic specialty DMTs may not only result in greater risk for disease activity but may also expose individuals to the potential for disease rebound, depending on the mechanism of action.